Skip to content
  • About us
  • Our focus
  • Team
    • Management board
    • Advisory board
  • Investors
  • Drug pipeline
  • News
  • Contact
Menu
  • About us
  • Our focus
  • Team
    • Management board
    • Advisory board
  • Investors
  • Drug pipeline
  • News
  • Contact

News

Home / Archives for October 2018

Month: October 2018

AGILeBiotics became a member of the BEAM Alliance

webmaster | Posted on 15 October 2018 |

AGILeBiotics became a member of the BEAM Alliance

We are proud to announce that AGILeBiotics is now a member of the BEAM Alliance, the European AMR innovation hub gathering Biopharma companies. Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 50 small and medium-sized European biopharmaceutical companies committed by developing innovative products to fend-off […]

Read moreAGILeBiotics became a member of the BEAM Alliance

Filed under: featured, News

Recent Posts

  • AGILeBiotics contributes to fight against future pandemic infections (e.g. COVID-19)
  • AGILeBiotics B.V. appoints new CEO Victor Schut
  • AGILeBiotics won the Investors Forum 2019 at the Dutch Life Sciences Conference
  • AGILeBiotics has been awarded the EUSMI-H2020 grant for up-scale synthesis of pre-clinical antibiotic candidate Toframicin
  • AGILeBiotics has received the Lead Development Voucher from the Netherlands Antibiotic Development Platform

Recent Comments

    Archives

    • April 2020
    • November 2019
    • October 2019
    • July 2019
    • June 2019
    • February 2019
    • October 2018
    • September 2018
    • August 2018
    • April 2018
    • February 2018
    • November 2017
    • October 2017
    • August 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017

    Categories

    • featured
    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    AGILeBiotics B.V. is a pharmaceutical company focusing on the development of novel antibiotics for the treatment of multi-drug resistant infections

    Linkedin

    Latest news

    AGILeBiotics contributes to fight against future pandemic infections (e.g. COVID-19)

    7 April 2020

    AGILeBiotics B.V. appoints new CEO Victor Schut

    6 April 2020

    AGILeBiotics won the Investors Forum 2019 at the Dutch Life Sciences Conference

    28 November 2019

    AGILeBiotics has been awarded the EUSMI-H2020 grant for up-scale synthesis of pre-clinical antibiotic candidate Toframicin

    14 October 2019

    Copyright © 2018 AGILeBiotics | All Rights Reserved. | Webdevelopment Skitter